← Leaderboards
John Troyer
Pharmathene, Inc.
$15,303,868
Attributed
$15,303,868
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.2M · FY2014–17$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
Funding mix
By agency
NIH$15,303,868 · 1
By mechanism
N01$15,303,868 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesAnthrax VaccinesCategoriesCold ChainsCommunicable DiseasesDisease OutbreaksResponseTechnologyAdvanced DevelopmentEventNational Institute Of Allergy And Infectious DiseasePathogenVaccine DevelopmentDrug FormulationsFormulation
Grant awards (4)
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$4,028,420
N01 · FY2017 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$3,818,071
N01 · FY2016 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$2,250,652
N01 · FY2015 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS$5,206,725
N01 · FY2014 · AI · contact PI